Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + EP in First-Line ES-SCLC
NCT03841136Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in small cell lung cancer (SCLC), sponsored by Fudan University. Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03841136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841136.